IRIS International | Biotech Hunter

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (5)

View all

Total Trials

5

As Lead Sponsor

4

As Collaborator

1

Total Enrollment

1,420

By Phase

PHASE3: 2NA: 1PHASE1: 1

By Status

TERMINATED: 2WITHDRAWN: 1COMPLETED: 1NO_LONGER_AVAILABLE: 1

Clinical Trials Pipeline4 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2021

2022

2023

2024

2025

2026

Today

NCT05199610

NCT05712941

Hover over trial bars to see details

Recent Trials

NCT05712941Lead Sponsor

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

PHASE3Withdrawn

Started: Apr 18, 2023 · Completed: Mar 31, 2025

NCT05493501Lead Sponsor

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

PHASE3Terminated

8 participants

Started: Dec 14, 2022 · Completed: Aug 31, 2023

NCT05003518Collaborator

ParentText User Engagement and Effectiveness Study

NATerminated

1,400 participants

Started: Jun 1, 2022 · Completed: Dec 1, 2022

NCT05199610Lead Sponsor

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

PHASE1Completed

12 participants

Started: Mar 30, 2022 · Completed: Apr 1, 2023

NCT05131438Lead Sponsor

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

N/ANO_LONGER_AVAILABLE